Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Lessons Learned From Lockdown: Viral Hepatitis–Related Liver Disease in the COVID-19 Era
  • CME
  • CE

Robert G. Gish, MD
Released: January 10, 2022
Back Next

References

  1. CEVHAP. Viral hepatitis. Fast facts. cevhap.org. Accessed December 29, 2021.
  2. World Health Organization. Global health sector strategy on viral hepatitis 2016-2021: towards ending viral hepatitis. Geneva: World Health Organization; 2016.
  3. Center for Systems Science and Engineering at Johns Hopkins University. COVID-19 dashboard. coronavirus.jhu.edu/map.html. Accessed December 29, 2021.
  4. Blach S, Kondili LA, Aghemo A, et al. Impact of COVID-19 on global HCV elimination efforts. J Hepatol. 2021;74:31-36.
  5. Wang Q, Davis PB, Xu R. COVID-19 risk, disparities and outcomes in patients with chronic liver disease in the United States. EClinicalMedicine. 2021;31:100688.
  6. Marjot T, Moon AM, Cook JA, et al. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: an international registry study. J Hepatol. 2021;74:567-577.
  7. Li Y, Regan J, Fajnzylber J, et al. Liver fibrosis index FIB-4 is associated with mortality in COVID-19. Hepatol Commun. 2021;5:434-445.
  8. Webb G, Marjot T, Cook J, et al. Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study. Lancet Gastroenterol Hepatol. 2020;5:P1008-1016.
  9. Rabiee A, Sadowski B, Adeniji N, et al. Liver injury in liver transplant recipients with coronavirus disease 2019 (COVID-19): U.S. multicenter experience. Hepatology. 2020;72:1900-1911.
  10. Colmenero J, Rodriguez-Peralvarez M, Salcedo M, et al. Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients. J Hepatol. 2021;74:148-155.
  11. Saviano A, Wrensch F, Ghany M, Baumert T. Liver disease and coronavirus disease 2019: from pathogenesis to clinical care. Hepatology. 2021;74:1088-1100.
  12. American Association for the Study of Liver Diseases. Clinical best practice advice for hepatology and liver transplant providers during the COVID-19 pandemic: AASLD expert panel consensus statement. aasld.org/about-aasld/covid-19-and-liver#consensus-statement. Accessed December 29, 2021.
  13. US Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes additional vaccine dose for certain immunocompromised individuals. fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-vaccine-dose-certain-immunocompromised. Accessed December 29, 2021.
  14. Centers for Disease Control and Prevention. CDC expands eligibility for COVID-19 booster shots to all adults. cdc.gov/media/releases/2021/s1119-booster-shots.html. Accessed December 29, 2021.
  15. Boyarsky B, Ou M, Greenberg R, et al. Safety of the first dose of SARS-CoV-2 vaccination in solid organ transplant recipients. Transplantation. 2021;105:e56-e57.
  16. Boyarsky B, Werbel W, Avery R, et al. Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients JAMA. 2021;325:1784-1786.
  17. Boyarsky B, Werbel W, Avery R, et al. Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA. 2021;325:2204-2206.
  18. American Association for the Study of Liver Diseases. AASLD expert panel consensus statement: vaccines to prevent COVID-19 in patients with liver disease. aasld.org/sites/default/files/2021-08/AASLD%20COVID-19%20Vaccine%20Document%20Update%208.30.2021.pdf. Accessed December 29, 2021.
  19. Nouri S, Khoong E, Lyles C, et al. Addressing equity in telemedicine for chronic disease management during the COVID-19 pandemic. catalyst.nejm.org/doi/full/10.1056/CAT.20.0123. Accessed December 29, 2021.
  20. Arora S, Thornton K, Murata G, et al. Outcomes of treatment for hepatitis C virus infections by primary care providers. N Engl J Med. 2011;364:2199-2207.
  21. Project ECHO. How ECHO is making a difference. hsc.unm.edu/echo. Accessed December 29, 2021. 
Back Next

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings